A Phase I clinical trial to investigate the safety and tolerability of NK105 when co-administered with carboplatin once per week to Japanese patients with advanced solid cancers.

Trial Profile

A Phase I clinical trial to investigate the safety and tolerability of NK105 when co-administered with carboplatin once per week to Japanese patients with advanced solid cancers.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs NK 105 (Primary) ; Carboplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Nippon Kayaku
  • Most Recent Events

    • 09 Feb 2017 Status changed from recruiting to discontinued.
    • 14 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top